Jacobs Levy Equity Management, Inc Syros Pharmaceuticals, Inc. Transaction History

Jacobs Levy Equity Management, Inc

  • $23.2 Billion
  • Q2 2024

Shares

18 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2022

Aug 15, 2022
SELL
$0.69 - $1.21 $61,279 - $107,461
-88,811 Closed
0 $0
Q1 2022

May 16, 2022
SELL
$1.02 - $3.8 $14,788 - $55,096
-14,499 Reduced 14.03%
88,811 $106,000
Q4 2021

Feb 14, 2022
BUY
$3.26 - $4.66 $5,424 - $7,754
1,664 Added 1.64%
103,310 $337,000
Q3 2021

Nov 15, 2021
BUY
$4.08 - $5.66 $241,091 - $334,455
59,091 Added 138.86%
101,646 $454,000
Q2 2021

Aug 16, 2021
SELL
$5.01 - $7.48 $102,970 - $153,736
-20,553 Reduced 32.57%
42,555 $232,000
Q1 2021

May 17, 2021
SELL
$7.19 - $14.95 $427,747 - $889,405
-59,492 Reduced 48.53%
63,108 $472,000
Q4 2020

Feb 16, 2021
BUY
$6.66 - $14.66 $409,629 - $901,677
61,506 Added 100.67%
122,600 $1.33 Million
Q3 2020

Nov 16, 2020
SELL
$8.69 - $14.47 $54,990 - $91,566
-6,328 Reduced 9.39%
61,094 $540,000
Q2 2020

Aug 17, 2020
BUY
$5.21 - $11.03 $17,526 - $37,104
3,364 Added 5.25%
67,422 $719,000
Q1 2020

May 15, 2020
BUY
$4.46 - $9.2 $84,017 - $173,309
18,838 Added 41.66%
64,058 $380,000
Q4 2019

Feb 14, 2020
BUY
$4.52 - $10.1 $204,394 - $456,722
45,220 New
45,220 $312,000
Q2 2019

Aug 13, 2019
SELL
$5.5 - $9.75 $89,512 - $158,681
-16,275 Closed
0 $0
Q1 2019

May 14, 2019
SELL
$5.51 - $9.59 $474,873 - $826,504
-86,184 Reduced 84.12%
16,275 $149,000
Q4 2018

Feb 14, 2019
BUY
$5.55 - $11.34 $130,980 - $267,624
23,600 Added 29.93%
102,459 $571,000
Q3 2018

Nov 14, 2018
BUY
$9.74 - $12.92 $21,428 - $28,424
2,200 Added 2.87%
78,859 $939,000
Q2 2018

Aug 14, 2018
BUY
$10.16 - $13.65 $778,855 - $1.05 Million
76,659 New
76,659 $783,000
Q1 2018

May 15, 2018
SELL
$9.47 - $12.98 $162,599 - $222,866
-17,170 Closed
0 $0
Q4 2017

Feb 13, 2018
BUY
$8.45 - $17.48 $145,086 - $300,131
17,170
17,170 $167,000

About Syros Pharmaceuticals, Inc.

SYRS Quotes by TradingView
  • Ticker SYRS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 20,236,200
  • Market Cap $43.1M
  • Description
  • Syros Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of treatments for cancer and monogenic diseases, and building a pipeline of gene control medicines. The company's lead product candidates are Tamibarotene, a selective retinoic acid receptor alpha agonist, which is in Phase III clinical trial for genomically def...
More about SYRS
Track This Portfolio

Track Jacobs Levy Equity Management, Inc Portfolio

Follow Jacobs Levy Equity Management, Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Jacobs Levy Equity Management, Inc, based on Form 13F filings with the SEC.

News

Stay updated on Jacobs Levy Equity Management, Inc with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email